Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Donald Zuhn — In a press release issued earlier this month, MPEG LA, LLC announced that it was launching an initiative to enhance the availability of gene patents for diagnostic testing. MPEG LA, which describes itself as the world's leading packager of patent pools for standards and other technology platforms, would accomplish this…
-
By Donald Zuhn –- On Friday, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its latest MoneyTree Report on venture funding. The study, conducted with PriceWaterhouseCoopers based on data from Thomson Reuters, indicates that venture capitalists invested $4.7 billion in 681 deals in…
-
By Donald Zuhn — Earlier today, VentureDeal, a venture capital database offering information on U.S. technology startup companies, venture capital firms, and company financings, released its latest quarterly venture capital funding reports covering the fourth quarter of 2009. The VentureDeal reports track venture capital funding in 15 technology-based sectors, with separate reports focusing on…
-
By Donald Zuhn –- On Friday, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its latest MoneyTree Report on venture funding. The study, conducted with PriceWaterhouseCoopers and Thomson Reuters, indicates that venture capitalists invested $5.0 billion in 794 deals in the fourth quarter…
-
By James DeGiulio — Industry investor and analyst Steven Burrill (at right), CEO of Burrill & Co., reports that a record $55.8 billion was raised by the biotech industry in 2009, which constitutes an 85 percent increase over the $30.1 billion recorded in 2008. Mr. Burrill noted that these results were driven by $37…
-
By Donald Zuhn — On New Year's Eve, we kicked off our third annual list of top biotech/pharma stories by counting down the first three of the top ten stories covered on Patent Docs in 2009 (see "Top Stories of 2009: #10, #9, and #8"). Yesterday, we listed stories #7, #6, and #5 (see…
-
By Donald Zuhn — Over the past five months, biotech and pharma companies have increasingly turned to the stock market for much needed infusions of capital. In August, Nashville-based Cumberland Pharmaceuticals snapped a two-year industry dry spell when it conducted an initial public offering (IPO) that raised $85 million (see "Is Biotech/Pharma Beginning to…
-
By Donald Zuhn –– On Tuesday, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its latest venture funding study. The study, conducted with PriceWaterhouseCoopers and Thomson Reuters, indicates that venture capitalists invested $4.8 billion in 637 deals in the third quarter of 2009,…
-
By Donald Zuhn — In August, we noted negative economic indicators for the biotech/pharma industry were finally giving way to more positive signs (see "Is Biotech/Pharma Beginning to Bounce Back?"). Among the positive signs was the return of the biotech/pharma initial public offering (IPO), with Cumberland Pharmaceuticals becoming the first U.S. drug company to…
-
By Donald Zuhn — Last week, Dr. Simos Simeonidis, a Senior Biotechnology Analyst for Rodman & Renshaw, LLC, provided FierceBiotech with a list of five biotech companies to watch in the coming months ("Five Biotech Companies to Watch"). On Dr. Simeonidis' list were Poniard Pharmaceuticals, GTx, OncoGenex, MannKind Corp., and Rigel Pharmaceuticals. Dr. Simeonidis…
Patent Docs 